Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Breaking Research from The Atlas Study Group - Nonmuscle-Invasive Bladder Cancer News

Thursday, February 22, 2024 | 7:30 p.m. ET

AUANews Patient Editor Tom Hulsey will interview Dr. Sandip M. Prasad about the recently published findings of The Atlas Group in The Journal of Urology®, Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection ofBladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). This interview will focus on important insights from Dr. Prasad, including study need and importance, what the authors found, study limitations, interpretations for patient care, and more. This webinar will be live and encourage audience interaction and participation. Tune in for the latest updates from this important research ( 

Sandip Prasad, MD

Sandip Prasad, MD
Garden State Urology
Director of Genitourinary Surgical Oncology
Vice-Chair of Urology at Morristown Medical Center/Atlantic Health System in New Jersey
Clinical Associate Professor in the Department of Surgery at Rutgers-NJMS
Clinical Assistant Professor in Surgery at Thomas Jefferson University. 

Tom Hulsey headshot

Tom Hulsey
Patient Perspectives Associate Editor of AUANews
Past President of the North Texas Prostate Cancer Coalition